Literature DB >> 1017532

Cell-mediated immunity in epidermodysplasia verruciformis.

W Gliński, S Jablonska, A Langner, S Obalek, M Haftek, M Proniewska.   

Abstract

Investigations were performed in 6 cases of epidermodysplasia verruciformis and 2 healthy family members. Nonspecific cell-mediated immunity (CMI) was studied by measuring response to phytohemagglutinin (PHA) and concanavalin A (Con A), percentrages of E- and EAC-rosette-forming lymphocytes, bacterial skin tests, and allergic reactions to dinitrochloro-benzene (DNCB). Impairment of CMI was manifested by reduction in the percentage of E rosettes, and lowered response to PHA, and- to a lesser degree- to Con A. The immune response to DNCB sensitization was invariably negative. Impairment of CMI was greater in cases of long duration and with extensive lesions. The cases of similar duration and extent of lesions, which never showed tendency to tumor formation, were not different in CMI in comparison with cases with numerous tumors. Only in cases with very advanced tumors CMI was impaired parallel to the gravity of the patient's general condition.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1017532     DOI: 10.1159/000251060

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  10 in total

1.  Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis.

Authors:  G Orth; S Jablonska; M Favre; O Croissant; M Jarzabek-Chorzelska; G Rzesa
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

Review 2.  Immunopathology of papillomavirus-induced tumors in different tissues.

Authors:  S Jablonska; G Orth; M A Lutzner
Journal:  Springer Semin Immunopathol       Date:  1982

Review 3.  Immunopathology of papillomavirus-induced warts and skin cancers in immunodepressed and immunosuppressed patients.

Authors:  M A Lutzner
Journal:  Springer Semin Immunopathol       Date:  1982

Review 4.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

5.  EVER2 deficiency is associated with mild T-cell abnormalities.

Authors:  Amandine Crequer; Capucine Picard; Vincent Pedergnana; Annick Lim; Shen-Ying Zhang; Laurent Abel; Slawomir Majewski; Jean-Laurent Casanova; Stefania Jablonska; Gerard Orth; Emmanuelle Jouanguy
Journal:  J Clin Immunol       Date:  2012-08-19       Impact factor: 8.317

Review 6.  The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections.

Authors:  Maciej Lazarczyk; Patricia Cassonnet; Christian Pons; Yves Jacob; Michel Favre
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

7.  The relation between the type of immunoreactive cells found in human papillomavirus (HPV) lesions of the uterine cervix and the subsequent behaviour of these lesions.

Authors:  K Syrjänen; M Väyrynen; O Castrén; R Mäntyjärvi; M Yliskoski
Journal:  Arch Gynecol       Date:  1984

8.  EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation.

Authors:  Maciej Lazarczyk; Cécile Dalard; Myriam Hayder; Loïc Dupre; Béatrice Pignolet; Slawomir Majewski; Francoise Vuillier; Michel Favre; Roland S Liblau
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

9.  Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses.

Authors:  Sarah J de Jong; Elias Imahorn; Peter Itin; Jouni Uitto; Gérard Orth; Emmanuelle Jouanguy; Jean-Laurent Casanova; Bettina Burger
Journal:  Front Microbiol       Date:  2018-06-12       Impact factor: 5.640

10.  The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma.

Authors:  Jaime S Horton; Alexander J Stokes
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.